Colorectal cancer (CRC) (ICD-10 = C18-C20), also referred as bowel cancer, is the cancer of the colon, rectum, or rectosigmoid junction. It is a type of gastrointestinal malignancy originating from either the colon or the rectum. CRC is the second most lethal cancer after lung cancer, and the third most diagnosed malignant tumor worldwide (World Health Organization, 2022). The disease usually begins as non-cancerous polyps on the inner lining of the colon or rectum. Over time some types of polyps can change into cancer (American Cancer Society, 2020).
Early cases of CRC are often asymptomatic, however, can be detected by screening. CRC symptoms depend on the size and location of the cancer. Some commonly experienced symptoms include changes in bowel habit, diarrhea or constipation, feeling of bowel not being empty properly, blood in feces, abdominal pain, bloating, fatigue or tiredness, unexplained weight loss, and anemia (American Cancer Society, 2022).
This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the AJCC stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I-III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC. The following data describes epidemiology of CRC. In the 8MM, the publisher's epidemiologists forecast an increase in the diagnosed incident cases of CRC from 1,004,915 cases in 2021 to 1,317,175 cases in 2031, at an AGR of 3.11% over the forecast period. Men accounted for more diagnosed incident cases of CRC than women in the 8MM and it predominantly affects older adults. These findings are in line with the publisher's estimates and these trends are reflected in the publisher's forecast for the diagnosed incident cases for the 8MM.
The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the American Joint Committee on Cancer (AJCC) stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I-III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC.
The CRC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Early cases of CRC are often asymptomatic, however, can be detected by screening. CRC symptoms depend on the size and location of the cancer. Some commonly experienced symptoms include changes in bowel habit, diarrhea or constipation, feeling of bowel not being empty properly, blood in feces, abdominal pain, bloating, fatigue or tiredness, unexplained weight loss, and anemia (American Cancer Society, 2022).
This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the AJCC stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I-III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC. The following data describes epidemiology of CRC. In the 8MM, the publisher's epidemiologists forecast an increase in the diagnosed incident cases of CRC from 1,004,915 cases in 2021 to 1,317,175 cases in 2031, at an AGR of 3.11% over the forecast period. Men accounted for more diagnosed incident cases of CRC than women in the 8MM and it predominantly affects older adults. These findings are in line with the publisher's estimates and these trends are reflected in the publisher's forecast for the diagnosed incident cases for the 8MM.
Scope
The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the American Joint Committee on Cancer (AJCC) stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I-III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC.
The CRC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The Colorectal Cancer Epidemiology series will allow you to:- Develop business strategies by understanding the trends shaping and driving the global CRC market.
- Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CRC therapeutics in each of the markets covered.
- Understand magnitude of CRC population by stage at diagnosis, recurrence of stages I-III into stage IV disease, and molecular markers.
Table of Contents
1 Colorectal Cancer: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
